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ess: Paul.Corris@ncl.acSummary A 19-year-old female lung transplant recipient developed peripheral
eosinophilia and interstitial infiltrates on chest radiograph shortly after commencing
carbamazepine. A lung biopsy was consistent with interstitial pneumonitis and
following withdrawal of the drug and treatment with steroids her symptoms
resolved. This is the first described case of carbamezipine-induced pneumonitis in
the lung transplant population.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Carbamazepine is widely used in the treatment of
epilepsy, neuropathic pain and bipolar affective
disorder. A wide variety of side effects have been
attributed to its use, including haematological,
hepatic, neurological, cardiac, dermatological and
renal disorders.1,2 While pulmonary toxicity is rare,
interstitial pneumonitis, bronchiolitis obliterans
organising pneumonia, bronchospasm, pulmonary
oedema and pulmonary nodules have all been
reported.3,4Elsevier Ltd. All rights reserve
2231084;
.uk (P.A. Corris).In this report, we describe for the first time, a
case of carbamazepine-induced interstitial pneu-
monitis in a lung allograft recipient.Case report
A 19-year-old girl with advanced cystic fibrosis
(homozygous DF508) underwent bilateral lung
transplantation. The initial postoperative period
was complicated by persistent hypoxia with asso-
ciated infiltrates on chest radiograph. A clinical
diagnosis of acute rejection was made and the
patient responded well to augmentation with
methylprednisolone.
At 2 weeks post-transplantation the patient had a
generalised seizure, associated with hypomagne-
saemia and elevated cyclosporin levels, which wered.
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Figure 2 Consolidation of alveolar spaces by alveolar
macrophages and eosinophilic exudate.
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sant medication, but a further event 2 days later
prompted commencement of carbamazepine
therapy, with good effect.
One month later, she presented with fever and
worsening dyspnoea. She had oxygen saturations of
87% on room air and left basal crackles. Initial
investigations revealed a haemoglobin of 11.5 g/dl,
white cell count of 12.6 109/l, neutrophil count
of 9.63 109/l, platelet count of 338 109/l, urea
of 10.4mmol/l, creatinine of 86 mmol/l, bilirubin of
15 mmol/l, alkaline phosphatase of 117 IU/l, alanine
aminotransferase of 9 IU/l and a raised C reactive
protein of 146mg/l. Chest radiograph demon-
strated bilateral lower lobe infiltrates (Fig. 1).
Bronchoscopy with bronchoalveolar lavage and
transbronchial biopsies were performed, which
showed no evidence of acute rejection but yielded
scanty growth of pseudomonas spp., for which she
was commenced on meropenem.
There was no improvement 1 week later, with
worsening hypoxia and increased infiltrates on
chest radiograph (Fig. 1). A white cell count of
10.1 109/l with peripheral eosinophilia of
0.88 109(8.71%) was noted, and the patient
underwent a video-assisted thoracoscopic (VATS)
lung biopsy to establish a diagnosis. This showed
consolidation of alveolar spaces by collections of
macrophages with admixed fibrin. There was a
variable mild interstitial inflammatory infiltrate
composed of lymphocytes and plasma cells with
small numbers of eosinophils and reactive pneumo-
cyte hyperplasia (Fig. 2). These appearances
favoured a diagnosis of eosinophilic pneumonia
modified by immunosuppression. There was noFigure 1 Chest radiograph demonstrating bilateral,
predominantly basal infiltrates.evidence of acute rejection. Carbamazepine was
discontinued and her steroid dosage increased. The
peripheral eosinophilia had resolved within 1 week
and by 1 month the infiltrates on chest radiograph
were no longer apparent.Discussion
The combination of increasing dyspnoea, fever and
interstitial infiltrates on chest radiograph, the
failure of symptoms to resolve with appropriate
antibiotic therapy, together with peripheral eosi-
nophilia, a consistent lung biopsy and an appro-
priate interval between the commencement of
carbamazepine and onset of symptoms, 3,4 estab-
lished the diagnosis of carbamazepine hypersensi-
tivity. Furthermore, withdrawal of treatment
resulted in rapid resolution of the patients symp-
toms. This represents the first described case of
carbamazepine-induced interstitial pneumonitis in
a lung transplant patient.
Carbamazepine is a first-line agent for the
treatment of general tonic-clonic seizures. Like
many other antiepileptics, particularly phenytoin,
it accelerates cyclosporin metabolism, lowering its
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has a wider therapeutic index than phenytoin and
the relationship between dose and plasma concen-
trations is linear, lessening the necessity for
monitoring plasma drug concentrations and the
potential for toxicity. These factors lead to the
initial choice of carbamazepine for seizure control
in this patient.
Carbamazepine-induced interstitial pneumonitis
is a rare but well-described complication. The
mechanism of lung injury is believed to be an
immune-mediated hypersensitivity response.5 This
may partially explain the rarity of the condition in
lung transplantation, as this patient population are
on high dose immunosuppressant regimens, in this
case a combination of cyclosporin, azathioprine
and prednisolone. Carbamazepine-induced hyper-
sensitivity syndrome has been reported in associa-
tion with reactivation of viral infection, a common
problem in transplantation6; however, the case
involved human herpes virus 6 infection rather than
cytomegalovirus infection. Neither the patient nor
the donor had positive CMV serology and she was
therefore not on prophylactic medication. Other
features of CMV disease, such as leucopenia were
not present during the illness.
In conclusion, concomitant carbamazepine ther-
apy should be considered as a cause of interstitialpneumonitis in lung transplant recipients with
pulmonary infiltrates case of carbamazepine-
induced pneumonitis in the lung transplant
population.References
1. Case records of the Massachusetts General Hospital. Weekly
clinicopathological exercises. Case 26-1996. A seven-year-old
boy with fever, lymphadenopathy, hepatosplenomegaly, and
prominent eosinophilia. N Engl J Med 1996; 335(8): 577–84.
2. Salzman MB, Valderrama E, Sood SK. Carbamazepine and fatal
eosinophilic myocarditis. N Engl J Med 1997;336(12):878–9.
3. Milesi-Lecat AM, Schmidt J, Aumaitre O, Kemeny JL, Moinard
J, Piette JC. Lupus and pulmonary nodules consistent with
bronchiolitis obliterans organizing pneumonia induced by
carbamazepine. Mayo Clin Proc 1997;72(12):1145–7.
4. Wilschut FA, Cobben NA, Thunnissen FB, Lamers RJ, Wouters
EF, Drent M. Recurrent respiratory distress associated with
carbamazepine overdose. Eur Respir J 1997;10(9):2163–5.
5. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T,
Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells
in individuals allergic to sulfonamides, phenytoin, and
carbamazepine. J Immunol 1995;155(1):462–72.
6. Aihara Y, Ito SI, Kobayashi Y, Yamakawa Y, Aihara M, Yokota S.
Carbamazepine-induced hypersensitivity syndrome asso-
ciated with transient hypogammaglobulinaemia and reactiva-
tion of human herpesvirus 6 infection demonstrated by real-
time quantitative polymerase chain reaction. Br J Dermatol
2003;149(1):165–9.
